DELIVER-CARE - delegation and networking in chronic inflammatory diseases
- Conditions
- L40.0chronic inflammatory diseasesM05M06M07M45.0K50K51Seropositive rheumatoid arthritisOther rheumatoid arthritis
- Registration Number
- DRKS00023000
- Lead Sponsor
- Medizinische Hochschule Hannover
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- All
- Target Recruitment
- 602
1. Written consent to participate in the health care research study
2. Age: = 18 years
3. Patients with chronic inflammatory diseases in the fields of gastroenterology, rheumatology, dermatology with a doctor’s confirmed diagnosis of a chronic inflammatory disease at the start of therapy, change or escalation of therapy:
Rheumatology: patients with RA or SpA or PsA (ICD M05 or M06 each with subgroups or M07.0-M07.39, M45.0x)
Dermatology: Patients with PsO: ICD L40.0 with L40.7
Gastroenterology: Patients with IBD (ulcerative colitis or Crohn's disease): ICD K50 or K51 with subgroups
1. It is foreseeable that the patient will not be available for a one-year observation period.
2. Insufficient knowledge of German
3. Serious comorbidities at the discretion of the treating physician
4. Lack of ability to consent
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Primary Objective:<br>Patients with chronic inflammatory diseases (in the fields of gastroenterology, rheumatology and dermatology) who attend MFA consultation have at least as high health-related quality of life as patients in standard care.<br><br>Primary Endpoint:<br>The primary endpoint is defined as the difference between the intervention group (IG) and the control group (KG) in terms of health-related quality of life after 12 months (measured with the European Quality of Life 5 Dimensions and 3 Levels (EQ-5D-3L) and the Visual Analog Scale (VAS)).
- Secondary Outcome Measures
Name Time Method